Subscribe
shutterstock_1349461175_pavel_kapysh-3
Pavel Kapysh / Shutterstock.com
30 November 2023GenericsMuireann Bolger

Daiichi Sankyo secures nearly $46m legal fees in antibody arbitration

Final award follows and incorporates the August 2022 decision by the arbitrator denying all claims levied at the Japanese company | Dispute involves antibody drug conjugate technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
USPTO hands win to Daiichi Sankyo in cancer drug dispute
18 January 2024   The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals.
Americas
Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18 November 2020   Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
Americas
Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

The Quintara decision: Defining trade secrets in federal cases
To disclose or not: Pharma patents face new AI reality
Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech